"Nitriles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
| Descriptor ID |
D009570
|
| MeSH Number(s) |
D02.626
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitriles".
Below are MeSH descriptors whose meaning is more specific than "Nitriles".
This graph shows the total number of publications written about "Nitriles" by people in this website by year, and whether "Nitriles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 5 | 5 |
| 2006 | 2 | 3 | 5 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 4 | 6 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 7 | 7 |
| 2014 | 2 | 9 | 11 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 4 | 6 |
| 2017 | 2 | 5 | 7 |
| 2018 | 3 | 4 | 7 |
| 2019 | 0 | 6 | 6 |
| 2020 | 2 | 4 | 6 |
| 2021 | 4 | 8 | 12 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nitriles" by people in Profiles.
-
Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide. Cancer Med. 2023 08; 12(15):16490-16501.
-
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023 06 20; 41(18):3352-3362.
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate. 2022 09; 82(13):1237-1247.
-
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
-
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 05 20; 40(15):1616-1622.
-
Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
-
Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv. 2021 09 14; 5(17):3492-3496.
-
The gut microbiome in konzo. Nat Commun. 2021 09 10; 12(1):5371.
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2022 02; 25(2):274-282.
-
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.